Could Mesothelioma Chemotherapy Ever Be Obsolete?

Treatment & Doctors
Reading Time: 4 mins
Publication Date: 06/01/2018
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us

Testimonials

"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Lashawn
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite Asbestos.com’s Article

APA

Povtak, T. (2022, February 2). Could Mesothelioma Chemotherapy Ever Be Obsolete? Asbestos.com. Retrieved February 4, 2023, from https://www.asbestos.com/news/2018/06/01/mesothelioma-chemotherapy-obsolete/

MLA

Povtak, Tim. "Could Mesothelioma Chemotherapy Ever Be Obsolete?" Asbestos.com, 2 Feb 2022, https://www.asbestos.com/news/2018/06/01/mesothelioma-chemotherapy-obsolete/.

Chicago

Povtak, Tim. "Could Mesothelioma Chemotherapy Ever Be Obsolete?" Asbestos.com. Last modified February 2, 2022. https://www.asbestos.com/news/2018/06/01/mesothelioma-chemotherapy-obsolete/.

Oncologist Dr. Arek Dudek at Regions Hospital Cancer Care Center in St. Paul, Minnesota, believes his clinical trial involving a novel immunotherapy combination could change the way doctors treat pleural mesothelioma.

Dudek is opening the only Phase II trial evaluating the combination of nivalumab (Opdivo) and ramucirumab (Cyramza) for previously treated mesothelioma patients.

“This strategy – if successful, like we think it will be – could make treatment with chemotherapy obsolete,” Dudek told Asbestos.com. “People can be really excited about this one.”

He based his optimism on the potential synergy between the two drugs that already have shown effectiveness for treating cancer as single agents.

“What’s unique about this study is that it adds another dimension to immune therapy,” he said. “It’s a two-prong approach that could make a huge difference. Each drug affects the tumor, and its ability to avoid the immune system, in a different way.”

Mesothelioma Trial Will Expand Soon

Although it opens only at Regions Hospital this month, three other study sites are expected to begin recruiting for the trial soon.

The sites include:

  • University of Illinois Cancer Center, Chicago
  • University of Minnesota Cancer Center, Minneapolis
  • Indiana University Cancer Center, Indianapolis

The goal for the second-line trial is to accrue 35 participants whose disease has progressed after chemotherapy. The trial is expected to run until 2021, and designed to measure response rate, progression-free survival, and a two-year overall survival.

“I’m very hopeful that the results will change the way we treat this cancer,” he said. “Immune checkpoint inhibitor therapy for mesothelioma has shown it does have some effectiveness, but given alone, the effectiveness is low. We’re hoping to at least double mesothelioma responses by combining two agents.”

No new mesothelioma treatments or drugs have been approved by the FDA for the treatment of mesothelioma since pemetrexed chemotherapy was added to cisplatin 14 years ago. Neither of those has shown sustained effectiveness, leaving most patients without a second-line treatment.

scientists researching in lab
Clinical Trials for Mesothelioma
Get help improving your prognosis by finding a mesothelioma clinical trial today.

Future of Mesothelioma Treatment Is Here

Most oncologists believe some version of an immunotherapy combination will be the next treatment approved.

Dudek believes it could be the one he is working on today.

He has seen this combination work with kidney cancer in a previous trial. Similar combinations have done well with lung and bladder cancer.

The FDA already has approved nivolumab for certain lung cancers as well as colorectal, bladder, kidney and head and neck cancers.

Nine mesothelioma clinical trials worldwide are testing nivolumab, including the one trial with ramucirumab.

The FDA approved ramucirumab in combination with certain chemotherapies as a second-line treatment for some lung, stomach and colorectal cancers.

Ramucirumab, which is known as a monoclonal antibody, works by controlling tumor growth through decreasing the blood supply it needs to metastasize. It targets and kills the protein that stimulates blood vessel growth within the tumor.

Nivolumab works by blocking the particular protein that prevents a patient’s immune system from recognizing the tumor as foreign and allowing it to attack.

Unlike chemotherapy, immunotherapy typically doesn’t come with harsh side effects that make it difficult to continue. After a period of time, chemotherapy stops working with mesothelioma tumors. The average survival time after diagnosis is only 6-18 months.

“When chemotherapy fails a patient with mesothelioma, there isn’t much left to do,” Dudek said. “This combination brings a completely different level of engaging the immune system. And once you have the immune system active, it stays that way.”

The trial dosing will involve two-week cycles of back-to-back intravenous infusion, first of nivolumab and then ramucirumab.

“As a clinician, you don’t want to be too optimistic. I’ve seen where optimism can fade quickly,” Dudek said. “But we have experience with these agents. And we’ve seen similar drugs with kidney cancer that had a tremendous response. It’s worthwhile for patients to be part of this process.”

open book icon vector illustration
Medically Reviewed by Top Mesothelioma Doctors
Free Mesothelioma Guide